By Brian D. Pacampara | More Articles October 3, 2012 | <\/p>\n
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) has earned a respected four-star ranking. <\/p>\n
With that in mind, let's take a closer look at IBB and see what CAPS investors are saying about the ETF right now. <\/p>\n
iShares Nasdaq Biotechnology facts <\/p>\n
Sources: Morningstar and Motley Fool CAPS. <\/p>\n
On CAPS, 93% of the 177 members who have rated iShares Nasdaq Biotechnology believe the ETF will outperform the S&P 500 going forward. <\/p>\n
Earlier this year, one of those Fools, ravens9111, tapped iShares Nasdaq Biotechnology as a particularly smart way to get into the space: \"Playing individual biotech stocks is risky business. This is probably the least risky way to play the sector without taking a chance of waking up one morning to see the company's drug was rejected and opens down 50%+ on an FDA rejection.\" <\/p>\n
Owning exceptional ETFs is a surefire way to secure your financial future. Of course, despite a strong four-star rating, iShares Nasdaq Biotechnology may not be your top choice. <\/p>\n
If that's the case, our special report on ETFs highlights three funds that are poised to soar in the next recovery. It's 100% free, but won't last forever, so click here to access it now. <\/p>\n
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account. <\/p>\n<\/p>\n
The rest is here: By Brian D. Continue reading
\n4-Star ETFs Poised to Pop: iShares Nasdaq Biotechnology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"